Literature DB >> 11260172

Successful treatment of severe recalcitrant psoriasis with combination infliximab and methotrexate.

B Kirby1, A M Marsland, A J Carmichael, C E Griffiths.   

Abstract

Plaques of psoriasis contain increased levels of cytokines, including tumour necrosis factor-alpha (TNF-alpha), which are thought to be essential to the maintenance of the psoriatic process. We report the successful treatment of severe, recalcitrant psoriasis when infliximab (a monoclonal antibody to TNF-alpha) was used in combination with methotrexate.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11260172     DOI: 10.1046/j.1365-2230.2001.00753.x

Source DB:  PubMed          Journal:  Clin Exp Dermatol        ISSN: 0307-6938            Impact factor:   3.470


  5 in total

Review 1.  Biologic therapies in the treatment of psoriasis: a comprehensive evidence-based basic science and clinical review and a practical guide to tuberculosis monitoring.

Authors:  Raja K Sivamani; Heidi Goodarzi; Miki Shirakawa Garcia; Siba P Raychaudhuri; Lisa N Wehrli; Yoko Ono; Emanual Maverakis
Journal:  Clin Rev Allergy Immunol       Date:  2013-04       Impact factor: 8.667

Review 2.  Tumor necrosis factor-alpha in psoriasis and psoriatic arthritis: a clinical, genetic, and histopathologic perspective.

Authors:  David Kane; Oliver FitzGerald
Journal:  Curr Rheumatol Rep       Date:  2004-08       Impact factor: 4.592

3.  Biological therapy of psoriasis.

Authors:  Raja K Sivamani; Genevieve Correa; Yoko Ono; Michael P Bowen; Siba P Raychaudhuri; Emanual Maverakis
Journal:  Indian J Dermatol       Date:  2010 Apr-Jun       Impact factor: 1.494

4.  The role of TNF inhibitors in psoriasis therapy: new implications for associated comorbidities.

Authors:  John Yost; Johann E Gudjonsson
Journal:  F1000 Med Rep       Date:  2009-05-08

Review 5.  Use of biologic agents in combination with other therapies for the treatment of psoriasis.

Authors:  Jennifer C Cather; Jeffrey J Crowley
Journal:  Am J Clin Dermatol       Date:  2014-12       Impact factor: 7.403

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.